 |
Hamartomatous Polyposis Syndromes CME DisclosuresRelease Date: August 27, 2007; Valid for credit through August 27, 2008 |
| Physicians - maximum of 1.0 AMA PRA Category 1 Credit(s)™ for physicians | |
| Contents of This CME Activity | |
| Hamartomatous polyposis syndromes are a heterogeneous group of inherited autosomal dominant syndromes that predispose to cancers and have divergent clinical features, and together account for less than 1% of colon cancer cases. They include juvenile polyposis syndrome, Peutz-Jeghers syndrome, and PTEN hamartoma tumor syndrome, which includes Cowden's syndrome, Bannayan-Riley-Ruvalcaba syndrome, and all syndromes that are germline PTEN mutations. - Hamartomatous Polyposis Syndromes
Kevin M. Zbuk, MD
Charis Eng, MD
Go to Test Questions |
| Legal Disclaimer | |
| The material presented here does not necessarily reflect the views of Medscape or companies that support educational programming on www.medscape.com. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. Copyright © 2007 Medscape. |
|
|
 |
Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Medscape, LLC designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Contact This Provider
|
|
